Shared Resource Core C. Administration. Darell D. Bigner, M.D., Ph.D., Core Director Support is requested for an Administrative Core including effort for Dr. Darell Bigner as POI Program Director and Principal Investigator and Director of the Administrative Core. Dr. Bigner will provide oversight of the scientific and administrative activities of the program project grant. Dr. Bigner will chair the P01Executive Committee which includes all research project leaders and shared resource core directors (Drs. Michael Zaiutsky, John Sampson, James Vredenburgh, and Daniel Barboriak). Together they will foster communicafion and collaboration between the research projects and shared resource cores and monitor and assess progress. Dr. Bigner will meet weekly with research project leaders and shared resource core directors, and he and his staff will serve as the editorial review/clearinghouse for all publications resulting from P01 activities. Dr. Bigner will plan and coordinate regular seminars which will include the POI project leaders, core directors and investigators. These seminars will be a part of the monthly Neuro-Oncology Program Seminar Series coordinated by Dr. Bigner. Dr. Bigner will coordinate the participafion of P01 investigators in national and international workshops, conferences, and meetings on brain tumor research. Also he will coordinate all the activities of the POI Internal and External Advisory Committees and will serve as the POI liaison with other appropriate academic units within Duke University and with outside entities. Core support is requested for a Staff Specialist who will be responsible for scheduling all internal and external meetings, budgetary monitoring, and general administrative assistance. Core C will provide administrative support for all three research projects and the two shared resource cores.
The Administrative Core is necessary to coordinate all the scientific and administrative activities in the program project grant, all of which are designed to develop new, innovative, more effective, and less toxic treatments for CNS tumors.
|Bao, Xuhui; Chandramohan, Vidyalakshmi; Reynolds, Randall P et al. (2016) Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats. Invest New Drugs 34:149-58|
|Suryadevara, Carter M; Riccione, Katherine A; Sampson, John H (2016) Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity. Clin Cancer Res 22:5164-5166|
|Saraswathula, Anirudh; Reap, Elizabeth A; Choi, Bryan D et al. (2016) Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. Cancer Immunol Immunother 65:205-11|
|Mitchell, Duane A; Batich, Kristen A; Gunn, Michael D et al. (2015) Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519:366-9|
|PruszyÅ„ski, Marek; Åyczko, Monika; Bilewicz, Aleksander et al. (2015) Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals. Nucl Med Biol 42:439-45|
|Huang, Dong-Sheng; Wang, Zhaohui; He, Xu-Jun et al. (2015) Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer 51:969-76|
|Pruszynski, Marek; Koumarianou, Eftychia; Vaidyanathan, Ganesan et al. (2015) D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination. Nucl Med Biol 42:19-27|
|Pruszynski, Marek; Koumarianou, Eftychia; Vaidyanathan, Ganesan et al. (2014) Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. J Nucl Med 55:650-6|
|Choi, Jaeyeon; Vaidyanathan, Ganesan; Koumarianou, Eftychia et al. (2014) N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization. Nucl Med Biol 41:802-12|
|Congdon, Kendra L; Gedeon, Patrick C; Suryadevara, Carter M et al. (2014) Epidermal growth factor receptor and variant III targeted immunotherapy. Neuro Oncol 16 Suppl 8:viii20-5|
Showing the most recent 10 out of 19 publications